« Return to News | Drug Sponsors

Biocartis completes $44.5M series D funding

Friday, December 14, 2012 11:12 AM

Biocartis, a molecular diagnostics company developing and commercializing high quality, easy to use platforms and clinically relevant oncology assays, has completed a $44.5 million Series D equity funding entirely backed by existing investors.

The round was led by the Flemish investment company PMV, and included RMM, Valiance, Debiopharm Group, Korys, Philips, Johnson & Johnson Development, the family office of Dr. Paul Janssen, Luc Verelst, Benaruca and New Rhein Healthcare.

"Completing a major life sciences fundraising in today´s environment is recognition of the significant progress that Biocartis has made over the past year,” said Greg Parekh, the CEO of Biocartis. “We are now a commercial stage organization with a high quality team which has proven it can take platforms from development to commercialization. We now look forward to building our menu of oncology tests; validating, registering and launching the Apollo platform; growing our commercial presence and ultimately helping shape the diagnosis and treatment of cancer."

Rudi Pauwels, chairman and founder of Biocartis, added, "We have once more received a positive signal from our shareholders. They strongly believe in the potential of the company and our goal to becoming a fully integrated global molecular diagnostics company."

Following the fundraising, Roald Borré, representing PMV, will join the Biocartis board of directors.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.